Inactive Instrument

News CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Acquisition of CinCor Pharma complete	23-02-27	AQ
AstraZeneca Completes $1.8 Billion Acquisition of CinCor Pharma to Boost Cardiorenal Portfolio	23-02-24	MT
AstraZeneca closes CinCor buy; Enhertu wins Chinese approval	23-02-24	AN
CinCor Pharma : Acquisition/Asset Disposal - Form 8-K	23-02-24	PU
CINCOR PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-02-24	AQ
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Composite Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P Global BMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from S&P TMI Index	23-02-24	CI
CinCor Pharma, Inc.(NasdaqGM:CINC) dropped from NASDAQ Biotechnology Index	23-02-23	CI
Astrazeneca Finance And Holdings Inc. completed the acquisition of CinCor Pharma, Inc. from a group of shareholders.	23-02-22	CI
CINCOR PHARMA, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-02-21	AQ
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat	23-02-21	GL
CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat	23-02-21	AQ
CinCor Pharma, Inc. Announces Completion of End-of-Phase 2 Meeting with U.S. Food and Drug Administration on Anticipated Phase 3 Program for Baxdrostat in Hypertension	23-02-21	CI
CINCOR PHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CinCor Pharma, Inc. - CINC	23-01-24	BU
AstraZeneca Initiates Tender Offer For $2 Billion CinCor Takeover	23-01-23	MT
ADRs End Higher; AstraZeneca, Barclays Trade Actively	23-01-23	DJ
Biotech IPO Window to Reopen in 2023 Following Muted Activity in 2022, Oppenheimer Says	23-01-23	MT
AstraZeneca Unit Starts Tender Offer to Purchase CinCor Pharma	23-01-23	MT
North American Morning Briefing : Big Day For Bank -2-	23-01-13	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CinCor Pharma, Inc.

Equities

CINC

US17240Y1091

Summary

Filters